Video
Author(s):
Gopa Iyer, MD, discusses treatment-emergent hyperphosphatemia with erdafitinib in patients with metastatic urothelial cancer.
Gopa Iyer, MD, medical oncologist, Memorial Sloan Kettering Cancer Center, discusses treatment-emergent hyperphosphatemia with erdafitinib (Balversa) in patients with metastatic urothelial cancer.
In April 2019, the FDA granted accelerated approval to erdafitinib for the treatment of patients with locally advanced or metastatic urothelial cancer with an FGFR3 or FGFR2 alteration that has progressed on platinum-containing chemotherapy.
FGFR inhibitors like erdafitinib appear to increase phosphorus reabsorption in the body and lead to hyperphosphatemia, explains Iyer.
Generally, hyperphosphatemia can be controlled with dietary changes such as reducing dairy and meat intake and adding oral phosphate binders like sevelamer (Renagel), says Iyer.
Notably, phosphate levels indicate response to erdafitinib, says Iyer. The FDA designation recommends starting patients on erdafitinib at a daily dose of 8 mg. If a patient’s phosphate level is <5.5 mg/dL after 2 to 3 weeks of treatment, the dose should be increased to 9 mg once daily to increase FGFR inhibition.
Targeted Therapies for NSCLC With Nonclassical EGFR Mutations Grow Increasingly Personalized
Next-Generation Sequencing Data Inform IO Treatment Sequencing in NSCLC
Neoadjuvant Botensilimab Plus Balstilimab Yields High MPR Rates in CRC
Comparable Survival Outcomes Observed With Atezolizumab/Bevacizumab vs Tremelimumab/Durvalumab in First-Line HCC
Neoadjuvant Atezolizumab/Trastuzumab/Pertuzumab Is Effective and Safe in HER2+ Early Breast Cancer
Alisertib Plus Ibrutinib and Rituximab Shows Preclinical Efficacy in MCL Models
Venetoclax Plus Obinutuzumab Improves MRD Clearance in Previously Untreated CLL
Cancer Vaccine Shows Promise for Patients With Stage III and IV Kidney Cancer
2 Commerce Drive
Cranbury, NJ 08512